Bifidobacterium breve BR03™ (DSM 16604)
Allergy & Immunology
Anti-inflammatory Activity
Supports a healthy inflammatory response [in vitro]
Single strain
Blend
Finished dosage form
a) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
b) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
For information on blends containing BR03, see the following Blends pages:
- BIFIDERM®
- BIFISLIM® Junior
- BIFIACNEL®
- BIFICOL®
- BIFIBABY®
- CELIAFLORA™ JUNIOR
- PROBIAL® Vision UVEA
- BIFISPORT®
- GASTROBARRIER®
- BR03™ + B632™
- BR03™+ GG + BS01™ + BL03
- LA02 + BR03™ + LP01™ + LR06 + BS01™
Cardiometabolic Health
Blood Lipids
Supports healthy cholesterol metabolism [in vitro]
Blend
Finished dosage form
a) De Prisco A. et al. An interesting Mechanism of Cholesterol Reduction by Probiotic Strains. Poster from the 15th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health – IPC2022, held in Bratislava on 27-30 June 2022
For blends containing BR03, see the Blends and Products pages listed above.
Gastroenterology
BOWEL TRANSIT/OCCASIONAL CONSTIPATION
Reduces occasional constipation
Supports healthy intestinal transit time
1) 10 billion CFU
Single strain
Blend
Finished dosage form
1) Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 separately). CIBUS, 2005; 1(1):23-30.
For information on blends containing BR03, see the Blends and Products pages listed above.
a) Mogna L., et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl:S29-S32. doi:10.1097/MCG.0b013e31826852b7
b) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
c) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
e) Monzani R. et al. The Gut-Ex-Vivo System (GEVS) Is a Dynamic and Versatile Tool for the Study of DNBS-Induced IBD in BALB/C and C57BL/6 Mice, Highlighting the Protective Role of Probiotics. Biology (Basel). 2022 Oct 27;11(11):1574. doi: 10.3390/biology11111574.
Gastroenterology
Anti-pathogenic activity
Inhibits pathogenic E. coli [in vitro]
Supports a healthy immune response [in vitro]
Single strain
Blend
Finished dosage form
a) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
b) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
c) Deidda F. et al. L. rhamnosus LR04 DSM 16605, L. rhamnosus LR06 DSM 21981, L. pentosus LPS01 DSM 21980, L. plantarum LP01 LMG P-21021, L. plantarum LP02 LMG P-21020, L. delbr. Subsp. Delbrueckii LDD01 DSM 22106, B. breve BR03 DSM 16604 and B. breve B632 DSM 24706 strongly inhibit in vitro different Escherichia coli serotypes, including E. coli O157:H7. Poster presentation. 2012.
d) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
For information on blends containing BR03, see the Blends and Products pages listed above.
Healthy Aging
Antioxidant
Increases superoxide dismutase (SOD) production and elevates levels of reduced glutathione (GSH) [in vitro]
Supports normal immune function [in vitro]
Modulates healthy inflammatory response [in vitro]
Reduces production of oxidative ions [in vitro]
Single strain
Blend
Finished dosage form
a) Magistrelli L. et al. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Front Immunol. 2019 May 7;10:969. doi: 10.3389/fimmu.2019.00969
b) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
c) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47
Internal data on anti-inflammatory and antioxidant properties available upon request
For information on blends containing BR03™, see the Blends and Products pages listed above.
Neurology
NEURO-IMMUNE HEALTH
Supports healthy immune and antioxidant responses in blood cells [in vitro]
Single strain
Blend
Finished dosage form
a) Magistrelli L. et al. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Front Immunol. 2019 May 7;10:969. doi: 10.3389/fimmu.2019.00969.
b) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
c) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
For information on blends containing BR03™, see the Blends and Products pages listed above.
Urology
Genitourinary Health
Inhibits pathogenic E. coli [in vitro]
Supports a healthy inflammatory response [in vitro]
Supports healthy oxalate metabolism [in vitro]
Single strain
Blend
Finished dosage form
a) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
b) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
c) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
d) Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.
For information on blends containing BR03™, see the Blends and Products pages listed above.
